Page last updated: 2024-11-10

sk&f s-106203

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

SK&F S-106203: peptidoleukotriene receptor antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3035514
MeSH IDM0179432

Synonyms (11)

Synonym
skf s106203
(3s)-3-(2-carboxyethylsulfanyl)-3-[3-(8-phenyloctyl)phenyl]propanoic acid
sk&f 106203
skf 106203
benzenepropanoic acid, beta-((2-carboxyethyl)thio)-3-(8-phenyloctyl)-, (s)-
3-(2-carboxyethylthio)-3-(2-(8-phenyloctyl)phenyl)propanoic acid
sk&f-s106203
sk&f s-106203
129047-98-9
sk&f-s-106203
DTXSID30156044

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"In this report the pharmacologic and pharmacokinetic profile of the leukotriene receptor antagonist 3(S)-[(2-carboxyethyl)thio]-3-[2-(8-phenyloctyl)phenyl] propanoic acid (SK&F S-106203) in guinea-pigs is described."( Pharmacologic and pharmacokinetic profile of SK&F S-106203, a potent, orally active peptidoleukotriene receptor antagonist, in guinea-pig.
Eckardt, RD; Gleason, JG; Hay, DW; Muccitelli, RM; Novak, LS; Osborn, RR; Sarau, HM; Saverino, CM; Vickery-Clark, LM; Yodis, LA, 1991
)
0.73

Bioavailability

ExcerptReferenceRelevance
" When given orally, SK&F S-106203 is highly bioavailable and has a very long duration of action which correlates with the pharmacokinetic profile of the compound."( Pharmacologic and pharmacokinetic profile of SK&F S-106203, a potent, orally active peptidoleukotriene receptor antagonist, in guinea-pig.
Eckardt, RD; Gleason, JG; Hay, DW; Muccitelli, RM; Novak, LS; Osborn, RR; Sarau, HM; Saverino, CM; Vickery-Clark, LM; Yodis, LA, 1991
)
0.86

Dosage Studied

ExcerptRelevanceReference
" SK&F S-106203 produced dose-dependent rightward shifts in the LTC4 and LTE4 dose-response curves."( SK&F S-106203 inhibits leukotriene C4, leukotriene D4 and leukotriene E4 vasopressor responses in the conscious rat.
Eckardt, RD; Egan, JW; Newton, JF; Slivjak, MJ; Smith, EF, 1990
)
2.63
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (85.71)18.2507
2000's1 (14.29)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.37

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.37 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.37)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]